Absstract of: WO2023043986A1

This invention is directed to a product for use in avian subjects comprising a combination of in ovo vaccine and probiotic, and related methods.

Absstract of: AU2021324883A1

Provided are attenuated immunostimulatory bacteria with genomes that are modified to, for example, reduce toxicity and improve the anti-tumor activity, such as by increasing accumulation in the tumor microenvironment, particularly in tumor- resident myeloid cells, improving resistance to complement inactivation, reducing immune cell death, promoting adaptive immunity, and enhancing T-cell function. Also provided are immunostimulatory bacteria for use as vaccines, and for delivery of mRNA. The increase in colonization of phagocytic cells improves the delivery of encoded therapeutic products to the tumor microenvironment and to tumors and permits, among other routes, systemic administration of the immunostimulatory bacteria. The increase in colonization of phagocytic cells also provides for use of immunostimulatory bacteria for direct tissue administration for use as vaccines.

Absstract of: US2023086107A1

The present disclosure belongs to the technical field of pathogen detection, in particular to loop-mediated isothermal amplification (LAMP) primer sets for detecting porcine susceptibility-related pathogenic bacteria, and a kit, a LAMP chip and use based on the same. The LAMP primer sets for detecting porcine susceptibility-related pathogenic bacteria include an Actinobacillus pleuropneumoniae primer set, a Haemophilus parasuis primer set, a Salmonella choleraesuis primer set, a Bordetella bronchiseptica primer set, a Pasteurella multocida primer set, a Streptococcus suis primer set, and an Erysipelothrix rhusiopathiae primer set.

Absstract of: US2023090746A1

Helicobacter pylori is a leading cause of gastric mucosal inflammation, peptic ulcers, and gastric adenocarcinoma. Emerging antimicrobial-resistant H. pylori has hampered the successful eradication of frequent chronic infections. Additionally, due to the absence of effective vaccines against H. pylori, a safe vaccine is highly demanded. Disclosed herein are innovative Protective Immunity Enhanced Salmonella Vaccine (PIESV) vector strains to deliver and express multiple H. pylori antigen genes Immunization of mice with a vaccine delivering the HpaA, NapA (also termed Hp-NAP), UreA and UreB antigens, provided sterile protection against H. pylori SS1 infection in 7 out of 10 tested mice. Compared to the control groups that had received PBS or a PIESV with an empty vector, immunized mice exhibited specific and significant cellular recall responses and antigen-specific IgG2c, IgG1, total IgG and gastric IgA antibody titers. Importantly, the mice immunized with the vaccine candidate showed a significant reduction in a load of an unidentified Gram-positive rod-shaped bacteria in their stomach compared to the control groups. In conclusion, a Salmonella Typhimurium-based live vaccine delivering four antigens shows promise as a safe and effective vaccine against H. pylori infection.

Absstract of: CN115819525A

本发明公开了一种靶向肿瘤的伤寒毒素B亚基模拟肽及其应用。伤寒毒素B亚基模拟肽选自YQPB‑1：COOH‑Thr‑Gly‑Ser‑Gly‑Asn‑Ala‑Asn‑Val‑NH2等6条多肽中的任意一种。本发明所述的伤寒毒素B亚基模拟肽或其二聚体、多聚体在制备靶向肿瘤的的诊断试剂或肿瘤治疗药物中的应用。本发明开发了一系列新的模拟伤寒沙门菌分泌的伤寒毒素B亚基(PltB)的模拟肽，YQPB‑X系列的模拟肽能与神经节苷脂高表达的肿瘤细胞特异性结合，经活体光学成像和结果证实对神经母细胞瘤、非小细胞肺癌、黑色素瘤、乳腺癌和骨肉瘤等多种肿瘤具有优异的显像成果。

Absstract of: US2023082935A1

This invention is directed to a product for use in avian subjects comprising a combination of in ovo vaccine and probiotic, and related methods.

Absstract of: US2023077406A1

The invention enables efficient, rapid, and sensitive enumeration of living cells by detecting microscopic colonies derived from in situ cell division using large area imaging. Microbial enumeration tests based on the invention address an important problem in clinical and industrial microbiology—the long time needed for detection in traditional tests—while retaining key advantages of the traditional methods based on microbial culture. Embodiments of the invention include non-destructive aseptic methods for detecting cellular microcolonies without labeling reagents. These methods allow for the generation of pure cultures which can be used for microbial identification and determination of antimicrobial resistance.

Absstract of: WO2023039194A1

Provided herein is the ability for intravenous delivery of bacteria without the septic side-effects and for delivery of immune modulating proteins that are systemically toxic to be delivered directly to the tumor micro-environment without any systemic toxicity.

Absstract of: US2023081896A1

Provided herein is an air monitoring system with a venturi pump including an air supply passageway, a sample passageway, and a discharge passageway, the discharge passageway in fluid communication with the air supply passageway and the sample passageway, and a detection device including a biochip, a light emitting source, a photodetector, and a controller electronically coupled to the photodetector. Also provided herein is a photonic biogel and uses thereof for spectroscopic detection of airborne pathogens.

Absstract of: WO2021224640A1

There is provided compositions for the detection of target cellular material, the composition comprising: a chemically modified substrate; at least one binding moiety, wherein the binding moiety comprises a glycan; and at least one linker covalently linked to the substrate and the binding moiety by a first and second bond. There is also provided methods of preparation of such compositions and methods for detection of target cellular material, such as for detection of pathogenic microorganisms.

Absstract of: US2021347859A1

Formulations of egg powders with avian antibodies that act as mucosal protectants are provided. The formulations are effective for protecting the mucosal membranes in the pharyngeal area of an individual from viral infections. Formulations effective for reducing infections of SARS-CoV-2 in individuals are provided. Formulations are also effective for reducing transmission of viral disease. The formulations are tablets, candies, gummies, throat lozenges, and powders for administering to the pharyngeal area. Methods for administering the formulations for reducing viral disease such as Covid-19 are disclosed.

Absstract of: KR20230036741A

본 발명은 살모넬라 혈청형을 검출할 수 있는 PCR 프라이머 세트 및 이의 용도에 관한 것으로서, whole genome sequence를 기반으로 한 pan-genome 분석과 real-time PCR법을 사용하여 66개의 혈청형을 하나의 96-well plate로 동시에 검출할 수 있는 방법을 개발하였다. 595개의 대용량 살모넬라 유전체를 효율적으로 분석하였고, 모든 target 혈청형에는 모두 존재하고 다른 혈청형에는 전혀 존재하지 않는 혈청형 특이 바이오마커를 탐색하였다. 이들 바이오마커로부터 혈청형 특이 프라이머를 디자인하였고, 하나의 96-well plate에서 66개의 살모넬라 혈청형을 빠르고 정확하게 검출할 수 있는 real-time PCR법을 개발하였다. 개발된 real-time PCR을 이용하여 426개의 살모넬라 균주 및 29개의 병원성 박테리아 균주에 대한 적용 실험함으로써 개발된 방법의 특이성 및 유효성을 검증하였으며 이 결과로 개발된 real-time PCR법이 66개의 살모넬라 혈청형을 검출하기 위한 high-throughput diagnostic tool로 사용될 수 있음을 시사한다. 또한, 본 발명에서 개발된 방법은 DNA 추출부터 혈청형 예측 결과에 이르기까지 3시간 미만의 시간이 소요되며 샘플 당 하나의 96-well plate만 필요하므로 시간 및 비용 효율적인 방법이다.

Absstract of: WO2017143024A2

The present invention provides vaccine compositions and methods of producing such compositions. Other embodiments of the invention include methods of treating a pathogen infection, methods of vaccinating a subject against a pathogen infection, and methods for treating an antibiotic-resistance bacterial infection in a subject in need thereof. In further embodiments, the invention includes methods of decreasing the level of a pathogen in a subject having a pathogen infection, methods of increasing the surviving rate of a subject having a pathogen infection, methods of reducing the level of pain associated with a pathogen infection, and methods of reducing the level of distress associated with a pathogen infection in a subject in need thereof. Novel scaffold compositions and opsonin-bound or lectin-bound pathogen compositions, and uses thereof, are also provided herein.

Absstract of: AU2021320392A1

The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Cell Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disorders, such as cancer, infection, and inflammation, in a subject.

Absstract of: US2023072505A1

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella, or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin− and/or pagP−. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd−, purI−, and msbB−. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and/or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and/or are modified to induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.

Absstract of: WO2021222182A1

In a general aspect, microorganisms [e.g., bacteria, etc.) are identified and detected. In some examples, a liquid solvent is supplied through a first channel of a sampling probe to an internal reservoir of the sampling probe; a fixed volume of the liquid solvent in the internal reservoir is held in direct contact with a sample surface for a period of time to form a liquid analyte; gas is supplied to the internal reservoir through a second channel of the sampling probe; the liquid analyte is extracted from the internal reservoir through a third channel of the sampling probe; the liquid analyte is transferred to a mass spectrometer; the mass spectrometer processes the liquid analyte to produce mass spectrometry data; and the mass spectrometry data are analyzed to detect and identify a microorganism [e.g., bacteria, fungi, or another type of microorganism) present at the sample surface.

Absstract of: WO2021222696A1

Disclosed herein are unique adjuvant compositions comprising an attenuated derivative of a self- destructing bacterial pathogen that undergoes lysis in vivo. In exemplary embodiments, the bacterial pathogen is a Salmonella spp. Also disclosed are methods for enhancing an immune response using the adjuvants disclosed herein.

Absstract of: CN115725482A

本发明公开一种减毒革兰氏阴性菌及其制备的OMV抗原递送系统，本发明公开了减毒革兰氏阴性菌，在野生型或原型菌株的基础上敲除或沉默基因fliC、fljB和磷酸乙醇胺转移酶基因EptA之后形成的菌株；菌株所形成的递送系统，具有低毒和T细胞佐剂效果，且能够正常扩增培养，具有重要的工业价值。可以用于制造预防性疫苗和肿瘤疫苗，可以实现注射或鼻喷等给药。

Absstract of: WO2023028422A1

A probiotic egg wash for the exterior surface of the eggshell that is ingested by the developing embryo resulting in an established GI tract microbiome that promotes health and outcompetes potential pathogens such as Salmonella is provided herein. In the preferred embodiment, the probiotic wash is composed at least of L. casei, L. rhamnosus, L. planitarum, L. paracasei, and/or B. lactis at a concentration of between 102 to 109 CPU per egg.

Absstract of: WO2023025815A1

The present invention relates to immunogenic compositions and their use in providing protection against illness caused by infection with Shigella. The immunogenic compositions comprise Shigella GMMA with particular doses of O-antigen.

Absstract of: JP2020073569A

To provide Shiga toxin effector polypeptides with reduced antigenicity and/or immunogenicity in mammals.SOLUTION: A polypeptide comprises a Shiga toxin effector region comprising an amino acid sequence derived from the A Subunit of a member of the Shiga toxin family. The Shiga toxin effector region comprises a disruption of at least one epitope region of the Shiga toxin A Subunit amino acid sequence selected from among specific sequences. The Shiga toxin effector region is capable of exhibiting a Shiga toxin effector function.SELECTED DRAWING: None

Absstract of: WO2023027604A1

The invention relates to a set of primers for amplifying the nucleotide sequence of the recA gene of Salmonella enterica sp. bacteria, a method for detecting Salmonella enterica sp. bacteria, a method of detecting an infection caused by Salmonella enterica sp. bacteria and a kit for detecting an infection caused by Salmonella enterica sp. bacteria.

Absstract of: US2023062057A1

A probiotic egg wash for the exterior surface of the eggshell that is ingested by the developing embryo resulting in an established GI tract microbiome that promotes health and outcompetes potential pathogens such as Salmonella is provided herein. In the preferred embodiment, the probiotic wash is composed at least of L. casei, L. rhamnosus, L. planitarum, L. paracasei, and/or B. lactis at a concentration of between 102 to 109 CFU per egg.

Absstract of: WO2021255684A1

A composition comprising Shigella-Tetravalent (4-valent Shigella) bioconjugates. That encompasses the Shigella O-polysaccharide antigens of serotypes Shigella flexneri 2a, 3a, 6 and Shigella sonnei covalently linked to the protein carrier.

Absstract of: WO2023027604A1

The invention relates to a set of primers for amplifying the nucleotide sequence of the recA gene of Salmonella enterica sp. bacteria, a method for detecting Salmonella enterica sp. bacteria, a method of detecting an infection caused by Salmonella enterica sp. bacteria and a kit for detecting an infection caused by Salmonella enterica sp. bacteria.